NCT00179686View on ClinicalTrials.gov

A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2005

Study Completion Date

July 31, 2006

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

CC-5013

Trial Locations (6)

19111

Fox Chase Cancer Center, Philadelphia

35294

Birmingham Cancer Center, Birmingham

60612

Rush Cancer Institute, Chicago

60637

University of Chicago, Chicago

70006

Cancer and Blood Institute, Metairie

77030

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Prologue Research International

INDUSTRY

lead

Celgene Corporation

INDUSTRY